Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Peking University

Status: Completed

Conditions: Advanced MDS Without Identical Sibling Donor

Treatments: Procedure: transplant with haploidentical donor

Study type: Observational

Funder types: Other

Identifiers

NCT01793675

PUPH IRB [2013] (04)

Details and patient eligibility

About

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source.

the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Enrollment: 116 patients

Sex: All

Ages: 2 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression
• without identical sibling donor

Exclusion criteria

• Contraindication to HSCT
• Pregnancy
• Mental illness

Trial design

116 participants in 1 patient group

haploidentical transplant

Description:

transplant with haploidentical donor

Treatment:

Procedure: transplant with haploidentical donor